Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma.

Authors :: Dima D
Orland M
Ullah F
Anwer F
Mazzoni S
Raza S
Chaulagain CP
Samaras C
Valent J
Williams L
Khouri J
Source :: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Nov; Vol. 23 (11), pp. 857-860. Date of Electronic Publication: 2023 Aug 01.
Publication Year :: 2023
Abstract: Competing Interests: Disclosure Shahzad Raza: advisory board for Kite, and Incyte. Faiz Anwer: Bristol Myers Squibb (consultancy, research funding and speakers bureau), Janssen (consultancy), Allogene Therapeutics (research funding). Jason Valent: Alexion, AstraZeneca Rare Disease (research funding). Jack Khouri: Janssen (consultancy), The other authors do not have any financial or non-financial potential conflicts of interest.

Subjects :: Humans
Neoplasm Recurrence, Local drug therapy
Bridged Bicyclo Compounds, Heterocyclic pharmacology
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Treatment Outcome
Retreatment
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Multiple Myeloma drug therapy

Full Text Access

Tools